Please provide your email address to receive an email when new articles are posted on . In TEMPO-1, fixed 5 mg and 15 mg doses of tavapadon improved outcomes in patients with Parkinson’s disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results